Premium
Broad‐Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View
Author(s) -
Felicetti Tommaso,
Manfroni Giuseppe,
Cecchetti Violetta,
Cannalire Rolando
Publication year - 2020
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000464
Subject(s) - broad spectrum , flavivirus , dengue fever , repurposing , zika virus , virology , dengue virus , yellow fever , identification (biology) , west nile virus , drug repositioning , flaviviridae , drug discovery , biology , host (biology) , computational biology , drug , virus , chemistry , bioinformatics , hepatitis c virus , pharmacology , genetics , combinatorial chemistry , ecology
Infections by flaviviruses, such as Dengue, West Nile, Yellow Fever and Zika viruses, represent a growing risk for global health. There are vaccines only for few flaviviruses while no effective treatments are available. Flaviviruses share epidemiological, structural, and ecologic features and often different viruses can co‐infect the same host. Therefore, the identification of broad‐spectrum inhibitors is highly desirable either for known flaviviruses or for viruses that likely will emerge in the future. Strategies targeting both virus and host factors have been pursued to identify broad‐spectrum antiflaviviral agents. In this review, we describe the most promising and best characterized targets and their relative broad‐spectrum inhibitors, identified by drug repurposing/libraries screenings and by focused medicinal chemistry campaigns. Finally, we discuss about future strategies to identify new broad‐spectrum antiflavivirus agents.